The tuberculosis pandemic--which way now?
Zumla
A
A
Centre for Infectious Diseases, Royal Free and University College Medical School, London, UK.
Mwaba
P
P
Squire
S B
SB
Grange
J M
JM
D000328:Adult; D000818:Animals; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D002417:Cattle; D002648:Child; D004196:Disease Outbreaks; D004197:Disease Reservoirs; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000472:pathogenicity*; D012293:Rifampin / Q000627:therapeutic use; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D014944:World Health Organization
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin